Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Xilio Therapeutics, Inc. (XLO) is named in a beneficial-ownership disclosure by six reporting persons: Logos Global Management LP, Logos Global Management GP LLC, Logos Opportunities Fund IV LP, Logos Opportunities IV GP LLC, William Arsani and Graham Walmsley. Each reports shared voting and dispositive power over 730,315 shares, representing 9.99% of the class.
The reported securities consist of pre-funded warrants to acquire 476,250 common shares and Series A Warrants to acquire 476,250 common shares; both are subject to a 9.99% beneficial ownership limitation. The percentage calculation uses 6,580,153 common shares outstanding as of August 10, 2026.
Key Figures
Reported beneficial ownership:730,315 sharesReported ownership percentage:9.99%Pre-funded warrants:476,250 shares+2 more
5 metrics
Reported beneficial ownership730,315 sharesEach of the six reporting persons; shared voting and dispositive power.
Reported ownership percentage9.99%Calculated using 6,580,153 common shares outstanding as of August 10, 2026.
Pre-funded warrants476,250 sharesCommon shares the warrants can acquire; subject to a 9.99% beneficial ownership limitation.
Series A Warrants476,250 sharesCommon shares the warrants can acquire; subject to a 9.99% beneficial ownership limitation.
Common shares outstanding6,580,153 sharesAs of August 10, 2026; used for the ownership percentage calculation.
Key Terms
pre-funded warrants, Series A Warrants, beneficial ownership limitation, shared dispositive power
4 terms
pre-funded warrantstechnical
"pre-funded warrants to acquire 476,250 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Series A Warrantstechnical
"Series A Warrants to acquire 476,250 shares"
Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.
beneficial ownership limitationregulatory
"subject to a 9.99% beneficial ownership limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
shared dispositive powerregulatory
"Shared Dispositive Power 730,315.00"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much XLO stock do the reporting persons report owning?
Each of the six reporting persons lists 730,315 shares as the beneficial-ownership amount, equal to 9.99% of XLO's common-stock class. The described securities are pre-funded warrants and Series A Warrants, each covering 476,250 common shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Xilio Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
98422T209
(CUSIP Number)
06/05/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
98422T209
1
Names of Reporting Persons
Logos Global Management LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
730,315.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
730,315.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
730,315.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
IA, PN
Comment for Type of Reporting Person: The securities reported herein consist of pre-funded warrants to acquire 476,250 shares of Common Stock and Series A Warrants to acquire 476,250 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. Percentage calculated based on 6,580,153 shares of Common Stock outstanding on August 10, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026.
SCHEDULE 13G
CUSIP Number(s):
98422T209
1
Names of Reporting Persons
Logos Global Management GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
730,315.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
730,315.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
730,315.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
OO, HC
Comment for Type of Reporting Person: The securities reported herein consist of pre-funded warrants to acquire 476,250 shares of Common Stock and Series A Warrants to acquire 476,250 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. Percentage calculated based on 6,580,153 shares of Common Stock outstanding on August 10, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026.
SCHEDULE 13G
CUSIP Number(s):
98422T209
1
Names of Reporting Persons
Logos Opportunities Fund IV LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
730,315.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
730,315.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
730,315.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The securities reported herein consist of pre-funded warrants to acquire 476,250 shares of Common Stock and Series A Warrants to acquire 476,250 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. Percentage calculated based on 6,580,153 shares of Common Stock outstanding on August 10, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026.
SCHEDULE 13G
CUSIP Number(s):
98422T209
1
Names of Reporting Persons
Logos Opportunities IV GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
730,315.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
730,315.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
730,315.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
OO, HC
Comment for Type of Reporting Person: The securities reported herein consist of pre-funded warrants to acquire 476,250 shares of Common Stock and Series A Warrants to acquire 476,250 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. Percentage calculated based on 6,580,153 shares of Common Stock outstanding on August 10, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026.
SCHEDULE 13G
CUSIP Number(s):
98422T209
1
Names of Reporting Persons
Arsani William
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
730,315.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
730,315.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
730,315.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: The securities reported herein consist of pre-funded warrants to acquire 476,250 shares of Common Stock and Series A Warrants to acquire 476,250 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. Percentage calculated based on 6,580,153 shares of Common Stock outstanding on August 10, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026.
SCHEDULE 13G
CUSIP Number(s):
98422T209
1
Names of Reporting Persons
Graham Walmsley
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
730,315.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
730,315.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
730,315.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
IN, HC
Comment for Type of Reporting Person: The securities reported herein consist of pre-funded warrants to acquire 476,250 shares of Common Stock and Series A Warrants to acquire 476,250 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. Percentage calculated based on 6,580,153 shares of Common Stock outstanding on August 10, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Xilio Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
828 Winter Street, Suite 300, Waltham, MA 02451
Item 2.
(a)
Name of person filing:
Logos Global Management LP ("Logos Global")
Logos Global Management GP LLC ("Logos Global GP")
Logos Opportunities Fund IV LP ("Opportunities Fund")
Logos Opportunities IV GP LLC ("Logos GP")
Arsani William
Graham Walmsley
Logos Global is the investment adviser to investment funds, including Opportunities Fund. Logos Global GP is the general partner of Logos Global. Logos GP is the general partner of Opportunities Fund. Dr. William is the control person of Logos Global and Logos Global GP. Dr. William and Dr. Walmsley are control persons of Logos GP and the portfolio managers of Opportunities Fund.
The reporting persons are filing this statement jointly but not as members of a group, and they expressly disclaim membership in a group. Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Opportunities Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
(b)
Address or principal business office or, if none, residence:
One Letterman Drive, Building C, Suite C3-350, San Francisco, California 94129
(c)
Citizenship:
See Item 4 of the cover sheet for each reporting person.
(d)
Title of class of securities:
Common Stock
(e)
CUSIP Number(s):
98422T209
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Logos Global: 730,315
Logos Global GP: 730,315
Opportunities Fund: 730,315
Logos GP: 730,315
Arsani William: 730,315
Graham Walmsley: 730,315
(b)
Percent of class:
Logos Global: 9.99%
Logos Global GP: 9.99%
Opportunities Fund: 9.99%
Logos GP: 9.99%
Arsani William: 9.99%
Graham Walmsley: 9.99%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Logos Global: 0
Logos Global GP: 0
Opportunities Fund: 0
Logos GP: 0
Arsani William: 0
Graham Walmsley: 0
(ii) Shared power to vote or to direct the vote:
Logos Global: 730,315
Logos Global GP: 730,315
Opportunities Fund: 730,315
Logos GP: 730,315
Arsani William: 730,315
Graham Walmsley: 730,315
(iii) Sole power to dispose or to direct the disposition of:
Logos Global: 0
Logos Global GP: 0
Opportunities Fund: 0
Logos GP: 0
Arsani William: 0
Graham Walmsley: 0
(iv) Shared power to dispose or to direct the disposition of:
Logos Global: 730,315
Logos Global GP: 730,315
Opportunities Fund: 730,315
Logos GP: 730,315
Arsani William: 730,315
Graham Walmsley: 730,315
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Opportunities Fund holds the Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Logos Global Management LP
Signature:
/s/ Arsani William
Name/Title:
Managing Partner
Date:
11/16/2026
Logos Global Management GP LLC
Signature:
/s/ Arsani William
Name/Title:
Managing Member
Date:
11/16/2026
Logos Opportunities Fund IV LP
Signature:
/s/ Arsani William
Name/Title:
Managing Member
Date:
11/16/2026
Logos Opportunities IV GP LLC
Signature:
/s/ Arsani William
Name/Title:
Managing Member
Date:
11/16/2026
Arsani William
Signature:
/s/ Arsani William
Name/Title:
Reporting person
Date:
11/16/2026
Graham Walmsley
Signature:
/s/ Graham Walmsley
Name/Title:
Reporting person
Date:
11/16/2026
Exhibit Information
Exhibit 99.1 Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G